FRANKLIN, Mass., Dec. 16 /PRNewswire-FirstCall/ -- Sontra Medical Corporation announced today that the SonoPrep technology and applications in drug delivery and diagnosis will be presented at the 8th US - Japan Symposium on Drug Delivery Systems. The latest developments and breakthroughs in Sontra’s SonoPrep skin permeation technology will be presented. The conference is held every two years and brings together academic and industrial leaders from Japan and the United States to discuss drug delivery breakthroughs.
Thomas Davison, Ph.D., President and CEO of Sontra, will be presenting the capabilities and evolution of the SonoPrep technology at the opening plenary session being held on Sunday, December 18, 2005 at the Westin Maui in Lahaina, Hawaii. For more information: http://web.mit.edu/langerlab/8thsymposium/index.html
“It is a privilege to be invited to participate in this exciting exchange of ideas and opportunities in drug delivery,” stated Dr. Davison. “More significant to me personally is the honor that I have in presenting the advances made in Sontra’s skin permeation technology, which is the product of determination and brilliant scientific discovery by Sontra’s research and development team.”
Driven by the opportunity to expand the applications of SonoPrep, Sontra engineers and scientists developed expanded capabilities in drug delivery that will be incorporated into Sontra’s second generation SonoPrep instrument. These advances include the combination of iontophoresis and a larger treatment area, which will facilitate even faster onset and higher dose capabilities.
Looking toward the future and the requirements of self-administration of transdermal drugs and continuous monitoring at home to manage diabetes, Sontra engineers developed breakthrough technology that will be incorporated into the third generation of SonoPrep skin permeation instruments that will have the simplicity, size, portability and cost of an electric toothbrush. Dr. Davison stated, “Reduced cost, compact size and simplicity are significant design criteria for the diabetes management home glucose monitoring product and self- administered transdermal drug regimens.”
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science. Sontra’s SonoPrep ultrasound-mediated skin permeation technology combined with technical competencies in transdermal drug formulation, delivery systems and biosensors is creating a new paradigm in transdermal drug delivery and diagnosis. The SonoPrep technology is being developed for several billion dollar market opportunities, including continuous glucose monitoring and the transdermal delivery of large molecule drugs and vaccines. Sontra is currently marketing the SonoPrep device and procedure tray for use with topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
Investor Relations Contacts: Sontra Medical Corporation Sean Moran, Chief Financial Officer 508-530-0334
SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a variety of subjects including, for example, the expected benefits and efficacy of the SonoPrep device in connection with diagnostics, vaccine delivery, glucose monitoring and transdermal drug delivery, the expected benefits, features, market opportunities, distribution and market acceptance of the SonoPrep device and technology, the expected size of the markets for the SonoPrep device and technology, Sontra’s expected ability to commercialize additional products, and Sontra’s business, research and marketing strategies and product development plans. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: our technology is new and we may experience adverse results in research collaborations, product development, clinical trials, product evaluations, commercialization efforts, product distribution and market acceptance; markets for our products may develop slower than expected, or not at all; our sales cycle is lengthy and we are still developing sales and marketing strategies which may or may not prove effective; the SonoPrep device may not prove effective in connection with diagnostics, vaccine delivery, glucose monitoring and/or transdermal drug delivery; Bayer has retained co-exclusive rights to the hospital ICU market and may compete with Sontra in such market; we may experience difficulties or delays in obtaining regulatory approvals to market products resulting from development efforts or difficulties or delays associated with sources of regulatory-approved transdermal drugs and vaccines; failure to obtain and maintain patent protection for discoveries or commercial limitations imposed by patents owned or controlled by third parties would have an adverse effect on us; we depend upon strategic partners and third-party distributors to develop, commercialize, market and sell products based on our work; and we require substantial additional funding to conduct research and development and to expand commercialization, distribution and marketing activities. For detailed information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Sontra’s filings with the Securities and Exchange Commission, including Sontra’s most recent Quarterly Report on Form 10-QSB. Forward- looking statements represent management’s current expectations and are inherently uncertain. We do not undertake any obligation to update forward- looking statements made by us.
Sontra Medical Corporation
CONTACT: Sean Moran, Chief Financial Officer of Sontra MedicalCorporation, +1-508-530-0334
Web site: http://www.sontra.com//
